Coronary Artery Disease (CAD)ACTIONNCT07577609
AI-assisted CT for Risk Stratification in Coronary Artery Disease (ACTION)
An observational study of Coronary Artery Disease (CAD) and Computed Tomography Angiography, run by University of Galway at 1 site in Ireland.
Trial summary
The goal of this observational study is to learn if AI-assisted cardiac CT imaging can improve cardiovascular risk stratification and prediction of future coronary events in an adult population undergoing clinically indicated cardiac CT. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Coronary Artery Disease (CAD), Computed Tomography Angiography, Biomarkers
- How many people
- 10,000 participants
- Where
- 1 siteIreland
- Study dates
- 21 Dec 2022to 21 Dec 2032
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: All-comers adult population undergoing clinically indicated cardiac CT in routine clinical care
Who may be able to join
- Adults aged ≥18 years
- Undergoing clinically indicated cardiac CT
- Able and willing to provide informed consent
Who cannot join
- History of malignancy
- Abnormal renal function (e.g., eGFR or serum creatinine outside reference range)
- Contraindications to iodinated contrast agents or CT imaging
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Ireland1 site, 1 recruiting
- Recruiting
Clinical Research Facility
Galway
Eileen Coen, 0861455568, eileen.coen@universityofgalway.ie
About this study
Official title: Artificial Intelligence-assisted CT for Risk Stratification in COronary Artery Disease to PreveNt Future Coronary Events and Improve Outcomes
The goal of this observational study is to learn if AI-assisted cardiac CT imaging can improve cardiovascular risk stratification and prediction of future coronary events in an adult population undergoing clinically indicated cardiac CT.
The main questions it aims to answer are:
Read more
- Can AI-enhanced cardiac CT accurately assess cardiovascular risk in a real-world adult population?
- How do CT-derived plaque characteristics correlate with clinical, biochemical, and lifestyle risk factors? Researchers will compare subgroups (e.g., patients with different risk profiles, biomarkers, or imaging findings, and a subset undergoing OCT imaging) to see if differences in imaging and clinical parameters are associated with cardiovascular risk and plaque vulnerability.
Participants will:
- Provide informed consent and medical history/demographic information
- Undergo blood sampling for cardiovascular and metabolic biomarkers
- Have a resting ECG performed
- Complete a detailed lifestyle and health questionnaire
- Receive a non-invasive cardiac CT scan interpreted by an expert
- Potentially receive heart rate-lowering medication (e.g., metoprolol) if required for imaging quality
- Be referred for further clinical evaluation if clinically indicated 
Read the detailed description
The ACTION Registry (Artificial Intelligence-assisted CT for Risk Stratification in Coronary Artery Disease) is a prospective, single-centre, observational patient registry conducted at the Clinical Research Facility, University Hospital Galway.
This registry is designed to systematically collect and integrate multimodal data from adults undergoing clinically indicated cardiac computed tomography (CT) to support advanced cardiovascular risk assessment using artificial intelligence (AI)-based approaches.
Registry Design and Procedures Eligible participants are consecutively enrolled at the time of referral for clinically indicated cardiac CT. Following informed consent, data are collected during a single baseline visit and supplemented by routine clinical data and follow-up information where available.
Registry procedures include:
- Collection of demographic and clinical data from medical records
- Blood sampling for cardiovascular and metabolic biomarkers
- Resting electrocardiogram (ECG)
- Structured questionnaires capturing lifestyle, cardiovascular history, and risk factors
- Standard-of-care cardiac CT imaging acquisition and expert interpretation
- Recording of medication use and clinically relevant interventions A subset of participants undergoing invasive imaging (e.g., optical coherence tomography) will have additional data collected for cross-modality comparison.
Data Collection and Registry Variables
The registry captures structured data across the following domains:
- Clinical and demographic characteristics
- Laboratory biomarkers
- Imaging-derived parameters from cardiac CT
- Lifestyle and behavioural factors
- Treatment and medication data
All variables are defined in a standardized data dictionary, which specifies:
- Variable definitions and formats
- Source of data (e.g., imaging system, laboratory system, questionnaire)
- Coding standards where applicable
- Acceptable ranges and units Data Management and Quality Assurance All data are anonymised using unique participant identifiers and stored in secure, access-controlled electronic systems compliant with GDPR and institutional data governance policies.
A comprehensive quality assurance plan is implemented, including:
Data Validation and Entry Controls
- Electronic data capture systems incorporate predefined validation rules
- Range checks and logical consistency checks are applied at data entry
- Automated queries are generated for missing, inconsistent, or out-of-range values Data Monitoring and Auditing
- Periodic internal data reviews are conducted to ensure completeness and accuracy
- Selected variables undergo source data verification against original records (e.g., imaging reports, laboratory systems, case report forms)
- On-site or remote monitoring may be conducted in accordance with institutional policies Source Data Verification
- A predefined proportion of records will be cross-checked with source documents
- Discrepancies will be documented, reviewed, and resolved בהתאם standard procedures Standard Operating Procedures (SOPs)
Registry operations are governed by standardized procedures covering:
- Participant recruitment and consent
- Data collection and entry
- Imaging acquisition and reporting
- Laboratory data handling
- Data management and security
- Statistical analysis and reporting
- Adverse event identification and reporting (if applicable)
- Change management and protocol amendments Sample Size Considerations As an observational registry, the study aims to recruit a representative, real-world population of adults undergoing cardiac CT. The sample size is determined pragmatically based on recruitment feasibility and expected patient volume at the study site.
The anticipated sample size is sufficient to support:
- Multivariable modelling for risk prediction
- Subgroup analyses
- Development and validation of AI-based models Handling of Missing Data
Missing or incomplete data may arise due to non-response, unavailable records, or technical limitations. The registry implements the following approach:
- Real-time prompts to minimise missing data at entry
- Documentation of reasons for missingness where available
- Statistical handling using appropriate methods (e.g., multiple imputation, sensitivity analyses), depending on the extent and pattern of missing data Statistical Analysis Plan Analyses will be conducted in accordance with a predefined statistical analysis plan.
Approaches may include:
- Descriptive statistics for baseline characteristics
- Correlation analyses between imaging, clinical, and biomarker variables
- Regression modelling for risk prediction and association analyses
- Subgroup analyses across demographic and clinical strata
- Cross-modality comparisons for imaging validation
- Longitudinal analyses where follow-up data are available Model performance may be evaluated using appropriate metrics (e.g., discrimination, calibration, and reclassification measures).
Data Use and Future Applications
The registry is designed to support:
- Clinical research and hypothesis generation
- Development and validation of AI-based cardiovascular risk models
- Integration of imaging and clinical data for precision medicine approaches An anonymised dataset will be maintained for future research, subject to governance and ethical approvals.
Ethical and Regulatory Considerations The registry is conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Ethical approval will be obtained from the appropriate research ethics committee, and all participants will provide written informed consent prior to inclusion
- Conditions
- Coronary Artery Disease (CAD), Computed Tomography Angiography, Biomarkers, AI (Artificial Intelligence), Lipoprotein(a), Atheroscleroses, Coronary
- Keywords
- AI-assisted cardiac CT, Coronary CT angiography (CCTA), Cardiovascular risk stratification, Coronary plaque characterization, High-risk plaque, Machine learning, CT-FFR (fractional flow reserve), Coronary calcium scoring
- Medical subject headings
- Coronary Artery Disease, Myocardial Ischemia
What is being measured
The primary outcome is the main question the study is designed to answer.
Cardiovascular risk stratification using AI-assisted cardiac CT
Assessment of cardiovascular risk based on AI-enhanced cardiac CT imaging, including coronary artery calcium scoring, plaque characterization, and integrated risk prediction using clinical and imaging data.
Measured: Baseline
Secondary outcomes (6)
Correlation between CT-derived plaque characteristics and haematological biomarkers
Association between imaging-derived plaque features and blood biomarkers (e.g., CRP, lipid profile, ApoB/ApoA-1 ratio).
Measured: Baseline
Concordance between coronary CT angiography (CCTA) and optical coherence tomography (OCT)
Agreement between CT-derived plaque characteristics and OCT findings in a subset of participants.
Measured: Baseline (subset undergoing OCT)
Association between lifestyle factors and imaging-derived plaque risk features
ssociation between lifestyle factors (e.g., smoking, diet, occupation) and imaging-derived Parameters.
Measured: Baseline
Subgroup analyses of cardiovascular risk by demographic and clinical factors
Differences in imaging and risk profiles across subgroups (age, sex, comorbidities, hormonal history).
Measured: Baseline
Longitudinal changes in plaque composition in patients receiving statin therapy
Evaluation of plaque progression or regression over time in participants on statin treatment.
Measured: Baseline, 1 year, and annually up to 5 years
Feasibility and utility of CT-derived fractional flow reserve (CT-FFR) and AI-based risk models
Assessment of the applicability and performance of CT-FFR and AI-based models in risk prediction.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 May 2026
- Study start21 Dec 2022
- Primary completion21 Dec 2032 (estimated)
- Study completion21 Dec 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Artery Disease (CAD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 10,000 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- University of Galway
- Sponsor type
- University, hospital or other
- Collaborators
- Science Foundation Ireland
- Responsible party
- Principal investigator, Faisal Sharif, University of Galway
- Investigators
- Faisal Sharif, MBBS, PhD, FRCPI, FESC, FACC, Principal investigator, University of Galway
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07577609
- Sponsor's protocol ID
- C.A. 2792
- Acronym
- ACTION
- Status last verified
- May 2026
- First submitted
- 28 Apr 2026
- Last updated
- 11 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 11 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Artificial Intelligence-assisted CT for Risk Stratification in COronary Artery Disease to PreveNt Future Coronary Events and Improve Outcomes
- ClinicalTrials.gov ID
- NCT07577609
- Acronym / sponsor ID
- ACTION / C.A. 2792
- Conditions
- Coronary Artery Disease (CAD), Computed Tomography Angiography, Biomarkers, AI (Artificial Intelligence), Lipoprotein(a), Atheroscleroses, Coronary
- Keywords
- AI-assisted cardiac CT, Coronary CT angiography (CCTA), Cardiovascular risk stratification, Coronary plaque characterization, High-risk plaque, Machine learning, CT-FFR (fractional flow reserve), Coronary calcium scoring
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 10,000 participants (estimated)
- Lead sponsor
- University of GalwayUniversity, hospital or other
- Collaborators
- Science Foundation Ireland
- Study start
- 21 Dec 2022 (actual)
- Primary completion
- 21 Dec 2032 (estimated)
- Study completion
- 21 Dec 2032 (estimated)
- First posted
- 11 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn if AI-assisted cardiac CT imaging can improve cardiovascular risk stratification and prediction of future coronary events in an adult population undergoing clinically indicated cardiac CT.
The main questions it aims to answer are:
- Can AI-enhanced cardiac CT accurately assess cardiovascular risk in a real-world adult population?
- How do CT-derived plaque characteristics correlate with clinical, biochemical, and lifestyle risk factors? Researchers will compare subgroups (e.g., patients with different risk profiles, biomarkers, or imaging findings, and a subset undergoing OCT imaging) to see if differences in imaging and clinical parameters are associated with cardiovascular risk and plaque vulnerability.
Participants will:
- Provide informed consent and medical history/demographic information
- Undergo blood sampling for cardiovascular and metabolic biomarkers
- Have a resting ECG performed
- Complete a detailed lifestyle and health questionnaire
- Receive a non-invasive cardiac CT scan interpreted by an expert
- Potentially receive heart rate-lowering medication (e.g., metoprolol) if required for imaging quality
- Be referred for further clinical evaluation if clinically indicated 
Detailed description
The ACTION Registry (Artificial Intelligence-assisted CT for Risk Stratification in Coronary Artery Disease) is a prospective, single-centre, observational patient registry conducted at the Clinical Research Facility, University Hospital Galway.
This registry is designed to systematically collect and integrate multimodal data from adults undergoing clinically indicated cardiac computed tomography (CT) to support advanced cardiovascular risk assessment using artificial intelligence (AI)-based approaches.
Registry Design and Procedures Eligible participants are consecutively enrolled at the time of referral for clinically indicated cardiac CT. Following informed consent, data are collected during a single baseline visit and supplemented by routine clinical data and follow-up information where available.
Registry procedures include:
- Collection of demographic and clinical data from medical records
- Blood sampling for cardiovascular and metabolic biomarkers
- Resting electrocardiogram (ECG)
- Structured questionnaires capturing lifestyle, cardiovascular history, and risk factors
- Standard-of-care cardiac CT imaging acquisition and expert interpretation
- Recording of medication use and clinically relevant interventions A subset of participants undergoing invasive imaging (e.g., optical coherence tomography) will have additional data collected for cross-modality comparison.
Data Collection and Registry Variables
The registry captures structured data across the following domains:
- Clinical and demographic characteristics
- Laboratory biomarkers
- Imaging-derived parameters from cardiac CT
- Lifestyle and behavioural factors
- Treatment and medication data
All variables are defined in a standardized data dictionary, which specifies:
- Variable definitions and formats
- Source of data (e.g., imaging system, laboratory system, questionnaire)
- Coding standards where applicable
- Acceptable ranges and units Data Management and Quality Assurance All data are anonymised using unique participant identifiers and stored in secure, access-controlled electronic systems compliant with GDPR and institutional data governance policies.
A comprehensive quality assurance plan is implemented, including:
Data Validation and Entry Controls
- Electronic data capture systems incorporate predefined validation rules
- Range checks and logical consistency checks are applied at data entry
- Automated queries are generated for missing, inconsistent, or out-of-range values Data Monitoring and Auditing
- Periodic internal data reviews are conducted to ensure completeness and accuracy
- Selected variables undergo source data verification against original records (e.g., imaging reports, laboratory systems, case report forms)
- On-site or remote monitoring may be conducted in accordance with institutional policies Source Data Verification
- A predefined proportion of records will be cross-checked with source documents
- Discrepancies will be documented, reviewed, and resolved בהתאם standard procedures Standard Operating Procedures (SOPs)
Registry operations are governed by standardized procedures covering:
- Participant recruitment and consent
- Data collection and entry
- Imaging acquisition and reporting
- Laboratory data handling
- Data management and security
- Statistical analysis and reporting
- Adverse event identification and reporting (if applicable)
- Change management and protocol amendments Sample Size Considerations As an observational registry, the study aims to recruit a representative, real-world population of adults undergoing cardiac CT. The sample size is determined pragmatically based on recruitment feasibility and expected patient volume at the study site.
The anticipated sample size is sufficient to support:
- Multivariable modelling for risk prediction
- Subgroup analyses
- Development and validation of AI-based models Handling of Missing Data
Missing or incomplete data may arise due to non-response, unavailable records, or technical limitations. The registry implements the following approach:
- Real-time prompts to minimise missing data at entry
- Documentation of reasons for missingness where available
- Statistical handling using appropriate methods (e.g., multiple imputation, sensitivity analyses), depending on the extent and pattern of missing data Statistical Analysis Plan Analyses will be conducted in accordance with a predefined statistical analysis plan.
Approaches may include:
- Descriptive statistics for baseline characteristics
- Correlation analyses between imaging, clinical, and biomarker variables
- Regression modelling for risk prediction and association analyses
- Subgroup analyses across demographic and clinical strata
- Cross-modality comparisons for imaging validation
- Longitudinal analyses where follow-up data are available Model performance may be evaluated using appropriate metrics (e.g., discrimination, calibration, and reclassification measures).
Data Use and Future Applications
The registry is designed to support:
- Clinical research and hypothesis generation
- Development and validation of AI-based cardiovascular risk models
- Integration of imaging and clinical data for precision medicine approaches An anonymised dataset will be maintained for future research, subject to governance and ethical approvals.
Ethical and Regulatory Considerations The registry is conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Ethical approval will be obtained from the appropriate research ethics committee, and all participants will provide written informed consent prior to inclusion
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 5 Years
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- All-comers adult population undergoing clinically indicated cardiac CT in routine clinical care
Key inclusion criteria (3 listed)
- Adults aged ≥18 years
- Undergoing clinically indicated cardiac CT
- Able and willing to provide informed consent
Key exclusion criteria (3 listed)
- History of malignancy
- Abnormal renal function (e.g., eGFR or serum creatinine outside reference range)
- Contraindications to iodinated contrast agents or CT imaging
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Cardiovascular risk stratification using AI-assisted cardiac CT
Time frame: Baseline
Assessment of cardiovascular risk based on AI-enhanced cardiac CT imaging, including coronary artery calcium scoring, plaque characterization, and integrated risk prediction using clinical and imaging data.
6 secondary outcomes
Correlation between CT-derived plaque characteristics and haematological biomarkers
Time frame: Baseline
Concordance between coronary CT angiography (CCTA) and optical coherence tomography (OCT)
Time frame: Baseline (subset undergoing OCT)
Association between lifestyle factors and imaging-derived plaque risk features
Time frame: Baseline
Subgroup analyses of cardiovascular risk by demographic and clinical factors
Time frame: Baseline
Longitudinal changes in plaque composition in patients receiving statin therapy
Time frame: Baseline, 1 year, and annually up to 5 years
Feasibility and utility of CT-derived fractional flow reserve (CT-FFR) and AI-based risk models
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 May 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Coronary Artery Disease (CAD)
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
RecruitingEarly Phase 1
Thiamine Intervention and Coronary Artery Bypass Grafting
Coronary Heart Disease, Coronary Artery Bypass Grafting
Not yet recruitingObservational study
Preoperative Gastric Ultrasound and Anaesthetic Management in Patients Undergoing Coronary Artery Bypass Grafting
Preoperative Fasting, Pulmonary Aspiration During Anesthetic Induction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Faisal Sharif, MBBS, PhD, FRCPI, FESC, FACC principal investigator
University of Galway
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Disease (CAD) and Computed Tomography Angiography, run by University of Galway at 1 site in Ireland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Faisal Sharif (+353 91524222, faisal.sharif@universityofgalway.ie), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cardiovascular risk stratification using AI-assisted cardiac CT (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2026.